New research has found that combining immunotherapy with chemotherapy is safe and effective for people with advanced small cell cancers in the bladder and prostate. A research team led by UCLA Health Jonsson Comprehensive Cancer Center investigators has shown that combining pembrolizumab, an immunotherapy drug, with… Read More
Infinitopes presented three posters on its cancer vaccine discovery and development strategy, including one that has been recognised as a ‘top 100’ poster presentation, at the Society for Immunotherapy of Cancer (SITC) 2024, held in Houston, US, from 6-10 November. A spinout from Oxford University, supported by Cancer Research UK (CRUK),… Read More
Megan Thomas spoke with Dan Passeri, CEO of Cue Biopharma, about why the company’s pipeline of cytokine-based drugs are so promising for cancer treatment. MT: Why is this a promising area of oncology research? DP: Cytokines, such as interleukin 2 (IL-2), are potent immunostimulant molecules and well-characterised activators of T… Read More
New data supporting SOT201, a PD-1-targeting immunocytokine, in advanced solid tumours was presented at the 2024 Society for Immunotherapy of Cancer (SITC) Meeting in Houston, TX, US. SOT201 is a PD-1-targeted and cis-acting attenuated IL-15 agonist designed to preferentially activate PD-1+CD8+ T cells, inducing superior anti-tumour… Read More
Kathryn L Chapman, Head of Discovery Biology & Jürgen Moll CSO at Tesselate Bio, explore alternative approaches to synthetic lethality to target cancer cells that use alternative lengthening of telomersin. Synthetic lethality and targeted drugs are a clinically established approach Synthetic lethality (SL) is an established, clinical and commercial approach… Read More
Scientists have discovered a way to target elusive circular fragments of DNA that drive the survival of some of the most aggressive cancers, paving the way for future treatments. In three papers published today in Nature, scientists from the Cancer Grand Challenges team eDyNAmiC and their… Read More
Researchers at the Francis Crick Institute, working with the Amsterdam University Medical Centre, have found that immune cells are held back from fighting lung tumours by another type of cell. Drugs that block a cancer-causing protein called KRAS-G12C are approved for use in lung cancer but… Read More
Megan Thomas comments and speaks with experts to uncover the future of cancer research. Artificial intelligence (AI) It’s not whether AI should be used, it’s when and how. Until several hurdles are overcome, such as data quality, data privacy and security, as well as regulatory and ethical challenges, this is… Read More
Researchers have discovered that an eczema-linked protein helps ovarian cancer manipulate its environment to resist immunotherapy, suggesting the potential for a skin drug-based treatment. Scientists at the Icahn School of Medicine at Mount Sinai used spatial genomics technology and preclinical animal models, with tumour specimens from… Read More
Affibody has shared the results of preclinical studies with its radiotherapeutic agent 177Lu-ABY-271 for treatment of HER2-expressing metastatic disease. The data were presented at the Annual Congress of the European Association of Nuclear Medicine by investigator Yongsheng Liu in the Professor Tolmachev group, Uppsala University. Read More
The first patient has been dosed with PFL-002/VERT-002 in a Phase I/II first-in-human trial for patients with non-small cell lung cancer (NSCLC) with MET alterations. PFL-002/VERT-002 is a monoclonal antibody acting as a degrader of c-MET. MET, also known as hepatocyte growth factor receptor… Read More
A new clinical trial has launched to assess monoclonal antibody UCB4594 in people with advanced cancers. The first site for the study has opened at the National Institute for Health and Care Research (NIHR) Manchester Clinical Research Facility (CRF) at The Christie NHS Foundation Trust (The… Read More
The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting marketing authorisation for Novartis’ Kisqali (ribociclib). The positive opinion relates to the adjuvant treatment of adults with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) early breast cancer (EBC),… Read More
Cancer Research UK and Australian charity the Minderoo Foundation have committed £3 million to a clinical study designed to find better treatments for brain cancer. The research study will trial multiple new treatments for people in the UK living with glioblastoma. As part of the… Read More
Misetionamide (GP-2250) in combination with gemcitabine has demonstrated a good safety profile and potential therapeutic benefit in the treatment of pancreatic adenocarcinoma. Panavance Therapeutics revealed the interim data from its Phase I clinical study at the 2024 Visceral Medicine Congress in Leipzig, Germany. The… Read More
DDW Editor Reece Armstrong speaks to Tahi Ahmadi, MD, PhD, Executive Vice President & Chief Medical Officer, Head of Experimental Medicines, Genmab & Jacqueline Nielsen, PhD, Therapeutic Head, Hematology, AbbVie, about the recommendation and the development of epcoritamab. Earlier this year, the European Medicines Agenecy’s (EMA) Committee for Medicinal Products… Read More
